Eli Lilly and Company (NYSE:LLY)‘s stock had its “sell” rating reissued by investment analysts at BMO Capital Markets in a research note issued on Friday. They presently have a $73.00 target price on the stock. BMO Capital Markets’ price objective would suggest a potential downside of 10.90% from the company’s previous close.
Other equities research analysts have also recently issued research reports about the stock. TheStreet raised shares of Eli Lilly and from a “c+” rating to a “b+” rating in a research note on Tuesday, July 25th. Citigroup Inc. upped their price objective on shares of Eli Lilly and from $92.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, April 19th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $92.00 price objective (down previously from $94.00) on shares of Eli Lilly and in a research note on Saturday, April 29th. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $96.00 price objective for the company in a research note on Wednesday, April 12th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Eli Lilly and in a research note on Monday, April 17th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company. Eli Lilly and currently has a consensus rating of “Hold” and a consensus price target of $88.37.
Shares of Eli Lilly and (NYSE LLY) traded up 0.46% during mid-day trading on Friday, reaching $82.31. 2,745,233 shares of the company’s stock were exchanged. Eli Lilly and has a 52-week low of $64.18 and a 52-week high of $86.72. The firm has a market cap of $86.84 billion, a P/E ratio of 35.62 and a beta of 0.34. The company has a 50 day moving average price of $82.99 and a 200 day moving average price of $81.53.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. The firm had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.86 EPS. Analysts forecast that Eli Lilly and will post $4.16 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This report was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/08/04/bmo-capital-markets-reaffirms-sell-rating-for-eli-lilly-and-company-nyselly.html.
In related news, VP Michael J. Harrington sold 22,833 shares of the stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $79.97, for a total value of $1,825,955.01. Following the completion of the transaction, the vice president now directly owns 62,056 shares in the company, valued at approximately $4,962,618.32. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 215,000 shares of the stock in a transaction dated Tuesday, June 20th. The stock was sold at an average price of $83.05, for a total transaction of $17,855,750.00. Following the completion of the transaction, the insider now owns 124,475,804 shares of the company’s stock, valued at $10,337,715,522.20. The disclosure for this sale can be found here. Over the last quarter, insiders sold 669,733 shares of company stock valued at $55,845,287. 0.20% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock valued at $5,769,694,000 after buying an additional 2,181,701 shares during the last quarter. BlackRock Inc. raised its position in shares of Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after buying an additional 59,978,664 shares during the last quarter. State Street Corp raised its position in shares of Eli Lilly and by 1.6% in the first quarter. State Street Corp now owns 42,363,935 shares of the company’s stock valued at $3,563,230,000 after buying an additional 651,424 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Eli Lilly and by 8.4% in the first quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock valued at $764,597,000 after buying an additional 708,597 shares during the last quarter. Finally, Janus Capital Management LLC raised its position in shares of Eli Lilly and by 2.8% in the first quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock valued at $733,731,000 after buying an additional 237,619 shares during the last quarter. Institutional investors own 75.48% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Company Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.